Monte Rosa Therapeutic (GLUE) 2024 Wells Fargo Healthcare Conference summary

Company overview and strategy

• Focuses on rational design of molecular glue degraders, prioritizing selectivity and oral drug properties.

• Avoids other degradation approaches like PROTACs, citing unique advantages of molecular glues.

• Pipeline spans oncology, immunology, and neurology, with strategic partnerships to expand reach.

• Resource allocation is balanced between internal development and leveraging external expertise.

MRT-2359 (GSPT1 degrader) program

• Demonstrated selective efficacy in MYC-high tumors, sparing non-MYC-driven cells.

• Preclinical and clinical data show strong pharmacodynamic effects and favorable safety at low doses.

• Dose regimens (5/9 and 21/7) are being explored to optimize duration of GSPT1 degradation.

• Phase I data set will include safety, PK/PD, efficacy, and recommended phase II dose, with robust patient enrollment.

• Tumor types include non-small cell lung cancer, small cell lung cancer, high-grade neuroendocrine, and MYC-amplified tumors.

MRT-6160 (VAV1 degrader) program

• Targets VAV1, a key immune regulator, with high selectivity over VAV2/3.

• Preclinical tox studies show a clean safety profile, supporting phase I in healthy volunteers.

• Phase I SAD/MAD study underway, with data expected in Q1 2025; includes safety, PK, and multiple PD markers.

• Proof-of-concept studies planned in ulcerative colitis, rheumatoid arthritis, and other autoimmune indications.

• Strategy includes rapid signal generation in multiple indications to inform further development and potential partnerships.